Balboa United California Institute of Renal Research
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Demko, Zachary
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Completed
N/A
110
US
Natera, Inc.
Transplant Rejection, Allograft Rejection, Complications
08/24
08/24
Faravardeh, Arman
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT03438773: Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients

Recruiting
1
50
US
Envarsus, Tacrolimus
California Institute of Renal Research, Balboa Institute of Transplantation, University of California, San Diego
Kidney Transplant; Complications, Kidney Transplant Failure and Rejection
12/23
12/23
ProActive, NCT04091984: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry

Active, not recruiting
N/A
5000
US
Prospera
Natera, Inc., University of Maryland
Kidney Transplant Rejection
10/26
10/27
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Completed
N/A
110
US
Natera, Inc.
Transplant Rejection, Allograft Rejection, Complications
08/24
08/24
Gripp, Eva
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT03438773: Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients

Recruiting
1
50
US
Envarsus, Tacrolimus
California Institute of Renal Research, Balboa Institute of Transplantation, University of California, San Diego
Kidney Transplant; Complications, Kidney Transplant Failure and Rejection
12/23
12/23
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Completed
N/A
110
US
Natera, Inc.
Transplant Rejection, Allograft Rejection, Complications
08/24
08/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Demko, Zachary
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Completed
N/A
110
US
Natera, Inc.
Transplant Rejection, Allograft Rejection, Complications
08/24
08/24
Faravardeh, Arman
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT03438773: Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients

Recruiting
1
50
US
Envarsus, Tacrolimus
California Institute of Renal Research, Balboa Institute of Transplantation, University of California, San Diego
Kidney Transplant; Complications, Kidney Transplant Failure and Rejection
12/23
12/23
ProActive, NCT04091984: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry

Active, not recruiting
N/A
5000
US
Prospera
Natera, Inc., University of Maryland
Kidney Transplant Rejection
10/26
10/27
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Completed
N/A
110
US
Natera, Inc.
Transplant Rejection, Allograft Rejection, Complications
08/24
08/24
Gripp, Eva
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT03438773: Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients

Recruiting
1
50
US
Envarsus, Tacrolimus
California Institute of Renal Research, Balboa Institute of Transplantation, University of California, San Diego
Kidney Transplant; Complications, Kidney Transplant Failure and Rejection
12/23
12/23
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Completed
N/A
110
US
Natera, Inc.
Transplant Rejection, Allograft Rejection, Complications
08/24
08/24

Download Options